ClinicalTrials.gg
RecruitingNCT00733590PROSe-ICDUpdated Jan 20, 2026

Prospective Observational Study of the ICD in Sudden Cardiac Death Prevention

An observational study in Heart Failure, Congestive, Death, Sudden, Cardiac and Arrhythmia, sponsored by Johns Hopkins University. Recruiting at 4 sites in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-01-20.

Sponsored by Johns Hopkins University · Observational

How we know

From the registry’s dates

  • Started Jun 2003; still recruiting 23 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,500
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Heart Failure by Johns Hopkins University — 6 open to participants now, 7 under way, none of them phase 3. Heart Failure · Johns Hopkins University.

Planned enrollment
Largest of 10
1,500 · median 132
Started
2003
the only one that year
Observational
10 of 21
4 open now
Registered
3rd of 21
by date

Among the 21 studies in Heart Failure by Johns Hopkins University, this one has the largest planned enrollment of the 10 observational ones that give a count, is the only one that started in 2003, is one of 10 observational ones, and was the 3rd registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

6 of the 21 studies in Heart Failure by Johns Hopkins University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Heart Failure by Johns Hopkins University, or all of them as a file.
02

Study summary

The overall hypothesis of this study is that subtle interactions between structural (substrate) and functional (trigger) abnormalities of the heart, some of which are genetically-determined, can be used to identify patients at high risk of sudden cardiac death (SCD). Such information may be used to better define patients most likely to benefit from replacement of an internal defibrillator (ICD). The prospective, observational study to enroll, categorize and follow patients who receive an ICD pulse generator replacement for primary prevention of SCD (PROSe-ICD) was established to :

  1. to gain a better understanding of the biological mechanisms that predispose to SCD
  2. to develop readily determined clinical, electrocardiographic, genetic and blood protein markers identify patients with an increased risk of dying suddenly
Read the detailed description

PROSe-ICD is a multicenter prospective cohort study of patients who undergo ICD implantation for primary prevention of SCD, designed to compare patients who sustain SCD (as measured by an appropriate ICD firing for rapid ventricular tachycardia (VT) or rapid ventricular fibrillation (VF) to those who do not. The cohort for this observational study consists of patients with cardiomyopathy who have an ICD implanted for primary SCD prevention according to recent trials (MADIT II, SCD-HeFT, DEFINITE) and practice guidelines.

Patients are followed longitudinally for clinical, ECG, genomic and proteomic markers and for index events. The primary outcome variable is an appropriate adjudicated ICD firing for rapid ventricular tachycardia or fibrillation.

The study standardizes initial therapeutic ICD settings, reflecting the current standard of care rather than an intervention, because by definition the study cohort consists of patients without a history of malignant arrhythmia, in whom the ICD functions simply as a defibrillator rather than as a more complex device employing anti-tachycardia pacing or tiered therapy. In order to facilitate the identification of rhythms prompting ICD therapy, programming includes far field ventricular electrogram storage. For patients who have firings (appropriate or not), all subsequent clinical care (including drug and device prescriptions) will be managed independently by the clinical attending electrophysiologist/cardiologist according to the local standard of care, unaffected by the study protocol. For safety reasons, any clinically-significant data (such as symptomatic complaints or documented episodes of ventricular arrhythmia) obtained during the study will be promptly communicated to the clinical attending physician both by telephone and in writing.

After informed consent, patients undergo an initial history and examination conducted by an attending electrophysiologist. Thereafter, patients are generally seen by an ICD nurse every 3 months and are evaluated for the purposes of the study every six months. The physician and/or nurse will record the variables shown in Table D1 on paper forms or directly into REDCap, web-based entry form. At each routine clinic visit (Q 3 month intervals) the ICD will be interrogated and any episodes of ventricular tachycardia lasting >10 beats with a cycle length \< 400 ms, ventricular fibrillation, or any anti-tachycardia pacing or ICD therapies will be recorded. If a ventricular arrhythmia is detected blood will be drawn and a digital ECG will be performed as described for the 6 month follow up visits. Further evaluation and treatment of the arrhythmia will be managed independently by the clinical attending physician, who will be notified of the arrhythmia by telephone, with written confirmation and documentation. At alternate visits (every 6 months) the patient will be evaluated by an attending electrophysiologist, a 60cc blood sample will be obtained, a 5-minute digital ECG, and any additional laboratory and diagnostic testing will be performed as clinically indicated.

Data on clinical events (admission for myocardial infarction/acute coronary syndrome (MI/ACS), admission for congestive heart failure (CHF), diagnostic angiography, revascularization, ICD device revision) will be collected by medical record review. Patients will be followed for a minimum of ten years or until death, cardiac transplantation or ventricular assist device implantation. A patient who experiences an appropriate ICD firing will have been considered to meet the primary endpoint of the study but will continue to be followed, particularly for the development of adverse events. Investigators will continue to follow and leverage this population as well as enroll additional patients who have ICDs in place and are undergoing elective pacemaker generator (PG) replacement for end-of-life indicators. The aims of this proposal are:

  1. To determine if a panel of serum proteins and metabolites measured at baseline and at replacement identifies patients who will experience atrial septal defect (ASD) after PG replacement.
  2. To determine if cardiac magnetic resonance imaging (CMR) performed around the time of PG replacement identifies patients who will experience ASD after PG replacement.
  3. To determine if baseline and serial ECG markers that are measures of conduction, repolarization, autonomic tone (heart rate variability (HRV), QT interval variability (QTV), novel metrics such as entropy), VT inducibility with programmed electrical stimulation at the time of PG exchange, and the history of ICD shocks identifies patients who will experience ASD after ICD replacement.
  4. To determine if baseline levels and changes over time (up to 5-years) in clinical ECG, epigenetic, serum protein and metabolite markers predict ASD, overall survival and trajectory of the heart failure (HF) phenotype in patients with a primary prevention ICD.
  5. To review for changes over time on the cardiac magnetic resonance late gadolinium enhancement (CMR-LGE) studies for previously obtained CMRs and for new baseline CMRs.
  6. To test whether intra-myocardial fat on multi-detector computed tomography (MDCT) is as effective or adds additional utility to risk stratification for VA above that of CMR-LGE characteristics in ischemic cardiomyopathy patients who are candidates for ICD therapy or have in situ ICDs.

A clinical events committee comprised of three experienced electrophysiologists, who are not investigators on this study or in the Hopkins Reynolds Center, adjudicate whether ICD firings are appropriate and whether episodes of VT/VF are related to ischemia, based on reports of device interrogation and other clinical documentation.The events committee will also adjudicate deaths in the study as cardiac or non-cardiac and sudden or non-sudden by review of the medical records, records of interviews of family and friends and ICD interrogation. Death within one hour of symptom onset and/or VT/VF on ICD interrogation that was not corrected by the device is considered SCD. All other deaths will be adjudicated as non-sudden including any terminal or hospice chronic care patient whose ICD is programmed off.

03

Conditions studied

  • Heart Failure, Congestive
  • Death, Sudden, Cardiac
  • Arrhythmia
  • Cardiomyopathies

Keywords

  • defibrillator, implanted
  • genomics
  • electrocardiography
  • electrophysiological study
  • proteomics
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with ischemic or non-ischemic cardiomyopathy undergoing their initial ICD implant for primary prevention, or programmed generator replacements on participants originally implanted for primary prevention.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • History of acute MI at least 4 weeks old
  • Non-ischemic LV dysfunction for at least 9 months
  • Who have an (EF) \< or = to 35%
  • Undergone elective replacement indicator (ERI) generator replacement of an FDA-approved ICD for primary prevention of SCD within 24 months of enrollment.
  • Who have primary prevention implants.

Exclusion criteria

Exclusion Criteria:

  • ICD generator replacement for secondary prevention
  • Inability or unwillingness to provide valid
  • Class IV heart failure
  • Patients with pre-existing Class 1 indications for pacemaker therapy.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,500 participants (estimated)
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. Arrhythmic Sudden Death defined as a therapy from the ICD for rapid VT or VF or a ventricular arrhythmia not corrected by the ICD

    Time frame: 10 years

Secondary outcomes

  1. All cause mortality, cardiovascular (CV) mortality, heart transplant, left ventricular assist device (LVAD), and implantable cardioverter defibrillator (ICD) explantation, or ICD Disabled

    Time frame: Total period of observation in the study

07

Study locations

4 of 4 sites recruiting
08

References and documents

Publications

  • Gokhale TA, Dey S, Limpitikul WB, Gautam N, Al'Aref SJ, Cross B, Saba S, Estes NAM 3rd, Vaughan BL, Jones SR, Tomaselli GF, Wu KC, DeMazumder D. Combined Analysis of Cardiac Repolarization Entropy and Magnetic Resonance Imaging Enhances Risk Stratification of Patients Receiving a Primary-Prevention ICD. JACC Clin Electrophysiol. 2026 Feb 24:S2405-500X(26)00126-X. doi: 10.1016/j.jacep.2026.01.051. Online ahead of print. PubMed 41823943 ↗
  • Nauffal V, Zhang Y, Tanawuttiwat T, Blasco-Colmenares E, Rickard J, Marine JE, Butcher B, Norgard S, Dickfeld TM, Ellenbogen KA, Guallar E, Tomaselli GF, Cheng A. Clinical decision tool for CRT-P vs. CRT-D implantation: Findings from PROSE-ICD. PLoS One. 2017 Apr 7;12(4):e0175205. doi: 10.1371/journal.pone.0175205. eCollection 2017. PubMed 28388657 ↗
  • Cheng A, Zhang Y, Blasco-Colmenares E, Dalal D, Butcher B, Norgard S, Eldadah Z, Ellenbogen KA, Dickfeld T, Spragg DD, Marine JE, Guallar E, Tomaselli GF. Protein biomarkers identify patients unlikely to benefit from primary prevention implantable cardioverter defibrillators: findings from the Prospective Observational Study of Implantable Cardioverter Defibrillators (PROSE-ICD). Circ Arrhythm Electrophysiol. 2014 Dec;7(6):1084-91. doi: 10.1161/CIRCEP.113.001705. Epub 2014 Oct 1. PubMed 25273351 ↗
  • Cheng A, Dalal D, Butcher B, Norgard S, Zhang Y, Dickfeld T, Eldadah ZA, Ellenbogen KA, Guallar E, Tomaselli GF. Prospective observational study of implantable cardioverter-defibrillators in primary prevention of sudden cardiac death: study design and cohort description. J Am Heart Assoc. 2013 Feb 22;2(1):e000083. doi: 10.1161/JAHA.112.000083. PubMed 23525420 ↗
  • Tereshchenko LG, Cheng A, Fetics BJ, Butcher B, Marine JE, Spragg DD, Sinha S, Dalal D, Calkins H, Tomaselli GF, Berger RD. A new electrocardiogram marker to identify patients at low risk for ventricular tachyarrhythmias: sum magnitude of the absolute QRST integral. J Electrocardiol. 2011 Mar-Apr;44(2):208-16. doi: 10.1016/j.jelectrocard.2010.08.012. Epub 2010 Nov 20. PubMed 21093871 ↗
  • Stempniewicz P, Cheng A, Connolly A, Wang XY, Calkins H, Tomaselli GF, Berger RD, Tereshchenko LG. Appropriate and inappropriate electrical therapies delivered by an implantable cardioverter-defibrillator: effect on intracardiac electrogram. J Cardiovasc Electrophysiol. 2011 May;22(5):554-60. doi: 10.1111/j.1540-8167.2010.01958.x. Epub 2010 Nov 18. PubMed 21087331 ↗
  • Tereshchenko LG, Han L, Cheng A, Marine JE, Spragg DD, Sinha S, Dalal D, Calkins H, Tomaselli GF, Berger RD. Beat-to-beat three-dimensional ECG variability predicts ventricular arrhythmia in ICD recipients. Heart Rhythm. 2010 Nov;7(11):1606-13. doi: 10.1016/j.hrthm.2010.08.022. Epub 2010 Sep 29. PubMed 20816873 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2003 (actual). Primary completion is estimated for Mar 2028, 297 months after the start.

Of 799 non-industry observational studies under Heart Failure, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 100. This study's planned 297 months is above that.

Counting every sponsor, half of 982 studies reached it within 41 months; a quarter within 23 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 11, 2008
First posted
Aug 13, 2008
StartActual
Jun 2003
Primary completionEst.
Mar 2028
CompletionEst.
Mar 2029
Last update
Jan 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00733590
Responsible party
Sponsor
First posted
Aug 13, 2008
Start date
Jun 2003
Primary completion
Mar 2028 (estimated)
Completion
Mar 2029 (estimated)
Last update
Jan 20, 2026

Study contacts

Katherine Wu, MD
Contact
kwu@jhmi.edu
410-502-7283
Katherine C Wu, MD
principal investigator · Associate Professor of Medicine Johns Hopkins University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion